Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression. Treatment with Krazati (adagrasib) plus Erbitux ...

as a combination with Eli Lilly’s anti-EGFR-antibody Erbitux (cetuximab) to treat patients with KRAS G12C-mutated, locally advanced, or metastatic CRC who have previously received chemotherapy.

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum ... on personalized cancer care in the context of KRAS mutation status in colorectal cancer, the ...

Amgen's first-to-market KRAS inhibitor Lumakras has so far failed ... which claimed accelerated approval in combination with EGFR antibody Erbitux (cetuximab) for a similar CRC patient population ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

QTX3544 is an oral, G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor currently being evaluated in a Phase 1 clinical trial in patients with KRASG12V mutations. The mitogen-activated ...